• We specialize in small molecule inhibitors, agonists, antagonists and screening libraries!
Search Site
Home >> Screening Panel >> DiscoveryProbe™ Cardiovascular-related Compounds Panel
Related Products
DiscoveryProbe™ Cardiovascular-related Compounds Panel

DiscoveryProbe™ Cardiovascular-related Compounds Panel

Catalog No. L1004
Size Price Stock Qty
5mg/well $2,780.00 In stock

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Click and Customize the Panel with your own choices of compounds/size/quantities/chemical forms etc.

HTS Facility Partners

Featured Products of the Panel

Catalog No. Product Name Summary Targets CAS Number Smiles
A1009 ANP (1-11), rat Vasodilator Cardiovascular
A1041 Angiotensin (1-7) Vasoconstriction peptide hormone Cardiovascular 51833-78-4 CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N
A1042 Angiotensin II Potent vasopressor and a powerful stimulus for production and release of aldosterone from the adrenal cortex. Cardiovascular 68521-88-0 CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(CC3=CC=CC=C3)C(=O)O)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N.CC(=O)O
A1043 Angiotensin III (human, mouse) Aldosterone stimulator Cardiovascular 13602-53-4 CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(CC3=CC=CC=C3)C(=O)O)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)N
A1057 coagulation factor II (thrombin) B chain fragment [Homo sapiens] Trypsin-like serine protease Cardiovascular
A1105 BNP (1-32), human Brain natriuretic peptide Cardiovascular 114471-18-0
A1111 Endothelin-1 (1-15), amide, human Vasoconstrictor agent Cardiovascular
A1143 heparin cofactor II precursor (SERPIND1) fragment [Homo sapiens] Thrombin inhibitor Cardiovascular
Download the Cardiovascular-related Compounds Panel - XLSX       Download the Cardiovascular-related Compounds Panel - SDF

Quality Control

Related Biological Data

BNP (1-32), human

Advantages

  • Available in stock with overnight delivery and free shipping over $500
  • Cost-effective and competitive price to save your findings
  • Potent, selective and cell-permeable in inhibiting or activating target molecules
  • Diverse in chemical structure and route of administration (oral/i.m/i.v injection etc.)
  • Detailed files describing potency, selectivity and applications etc.
  • Supported by published data from top peer-reviewed journals
  • Guaranteed high quality with NMR and HPLC validation

Storage and Shipping Information

Solubility Soluble in DMSO Storage Desiccate at -20°C
Packaging 96 well plate Form Powder
General tips For obtaining a higher solubility , please warm the tube at 37°C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

Background

A wide range of well-characterized bioactive molecules that covers various targets related to cardiovascular system, including angiotensin and thrombin etc. Facilitate your research towards the insights of vascular disease, stroke, wound repair and cancer etc. Applicable in cellular assays, animal models and drug screenings etc.

References

1. Dasgupta C, Zhang L. Angiotensin II receptors and drug discovery in cardiovascular disease. Drug Discov Today. 2011 Jan;16(1-2):22-34. doi: 10.1016/j.drudis.2010.11.016. Epub 2010 Dec 13.
Abstract
Angiotensin II type 1 (AT1R) and type 2 (AT2R) receptors are expressed in most organs and tissues and are implicated in hypertension, endothelial dysfunction, and cardiovascular diseases. Certain variants of AT1R and AT2R are constitutively predisposed to higher cardiovascular risk and hypertension. In this review we focused on the structure, expression of angiotensin II receptors, their mode of action, role in cardiovascular pathobiology, and how cardiovascular diseases are programmed in utero. In addition, we described genetic variants of angiotensin receptors, and also discussed possible ways of therapeutic intervensions of Ang II stimulation.